227 related articles for article (PubMed ID: 9732927)
1. Slow-release lanreotide treatment in endocrine gastrointestinal tumors.
Tomassetti P; Migliori M; Gullo L
Am J Gastroenterol; 1998 Sep; 93(9):1468-71. PubMed ID: 9732927
[TBL] [Abstract][Full Text] [Related]
2. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
[TBL] [Abstract][Full Text] [Related]
4. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
[TBL] [Abstract][Full Text] [Related]
5. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
7. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
8. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
Tomassetti P; Migliori M; Corinaldesi R; Gullo L
Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
[TBL] [Abstract][Full Text] [Related]
9. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.
Eriksson B; Renstrup J; Imam H; Oberg K
Ann Oncol; 1997 Oct; 8(10):1041-4. PubMed ID: 9402179
[TBL] [Abstract][Full Text] [Related]
10. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
11. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
12. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
13. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.
Eriksson B; Janson ET; Bax ND; Mignon M; Morant R; Opolon P; Rougier P; Oberg KE
Digestion; 1996; 57 Suppl 1():77-80. PubMed ID: 8813476
[TBL] [Abstract][Full Text] [Related]
14. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma.
Gaztambide S; Vazquez JA
J Endocrinol Invest; 1999 Feb; 22(2):144-6. PubMed ID: 10195383
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of delayed-release lanreotide in the medical therapy of acromegaly].
Papi G; Magnoni I; Pesenti M; Gola M; Tavernari V; Velardo A
Minerva Endocrinol; 1998 Jun; 23(2):57-63. PubMed ID: 9844356
[TBL] [Abstract][Full Text] [Related]
17. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
[TBL] [Abstract][Full Text] [Related]
18. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
[TBL] [Abstract][Full Text] [Related]
19. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.
Rohaizak M; Farndon JR
ANZ J Surg; 2002 Sep; 72(9):635-8. PubMed ID: 12269913
[TBL] [Abstract][Full Text] [Related]
20. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma.
Di Leo A; Bajetta E; Ferrari L; Biganzoli L; Mariani L; Carnaghi C; Camerini E; Buzzoni R; Ruiz JM
Cancer; 1996 Jul; 78(1):35-42. PubMed ID: 8646723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
